Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1. Consort flow diagram.

Published byClaude Anthony Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 1. Consort flow diagram."— Presentation transcript:

1 Figure 1. Consort flow diagram.
From: Piloting a Remission Strategy in Type 2 Diabetes: Results of a Randomized Controlled Trial J Clin Endocrinol Metab. 2017;102(5): doi: /jc J Clin Endocrinol Metab | Copyright © 2017 Endocrine Society

2 Figure 2. RR of diabetes remission in the intervention groups compared with the control group based on the OGTT criteria. Complete diabetes remission was defined as a fasting plasma glucose < 6.1 mmol/L and 2-hour plasma glucose < 7.8 mmol/L on an OGTT and no chronic diabetes drugs. Partial or complete diabetes remission was defined as a fasting plasma glucose < 7.0 mmol/L and 2-hour plasma glucose < 11.1 mmol/L on an OGTT and no chronic diabetes drugs. From: Piloting a Remission Strategy in Type 2 Diabetes: Results of a Randomized Controlled Trial J Clin Endocrinol Metab. 2017;102(5): doi: /jc J Clin Endocrinol Metab | Copyright © 2017 Endocrine Society

3 Figure 3. RR of diabetes remission and regression in the intervention groups compared with the control group based on the HbA1C criteria. Complete diabetes remission was defined as HbA1C < 6.0% (42 mmol/mol) and no chronic diabetes drugs. Partial or complete diabetes remission was defined as HbA1C < 6.5% (48 mmol/mol) and no chronic diabetes drugs. Diabetes regression or remission was defined as HbA1C < 7.0% (53 mmol/mol) and no chronic diabetes drugs. From: Piloting a Remission Strategy in Type 2 Diabetes: Results of a Randomized Controlled Trial J Clin Endocrinol Metab. 2017;102(5): doi: /jc J Clin Endocrinol Metab | Copyright © 2017 Endocrine Society

4 Figure 4. Anthropometric outcomes
Figure 4. Anthropometric outcomes. (a) Percentage weight change from baseline (─■─, 8-week group; ─▲─, 16-week group; ─○─, control group). Means and standard errors of the means are shown. For the 8-week intervention group compared with the control group, P = at 8 weeks and P = at 16 weeks. For the 16-week intervention group compared with the control group, P = at 8 weeks, P = at 16 weeks, P < at 20 weeks, and P = at 28 weeks. (b) Change in waist circumference from baseline (─■─, 8-week group; ─▲─, 16-week group; ─○─, control group). Means and standard errors of the means are shown. For the 8-week intervention group compared with the control group, P < at 8 weeks, P = at 16 weeks, and P = at 20 weeks. For the 16-week group compared with the control group, P = at 8 weeks, P = at 16 weeks, P = at 20 weeks, and P = 0.01 at 28 weeks. From: Piloting a Remission Strategy in Type 2 Diabetes: Results of a Randomized Controlled Trial J Clin Endocrinol Metab. 2017;102(5): doi: /jc J Clin Endocrinol Metab | Copyright © 2017 Endocrine Society

Download ppt "Figure 1. Consort flow diagram."

Similar presentations

Canadian Diabetes Association Clinical Practice Guidelines Management of Stroke in Diabetes Chapter 27 Michael Sharma, Gord Gubitz.

Canadian Diabetes Association Clinical Practice Guidelines Management of Stroke in Diabetes Chapter 27 Michael Sharma, Gord Gubitz.
Diagnosis of diabetes. Diabetic symptoms Diabetic symptoms + venous sample for : –Random venous ≥ 11.1 mmol/l (4.4-7.8) –Fasting glucose > 7(

Diagnosis of diabetes. Diabetic symptoms Diabetic symptoms + venous sample for : –Random venous ≥ 11.1 mmol/l ( ) –Fasting glucose > 7(
Diabetes Prevention for a Heterogeneous Population Richard Arakaki, M.D. Professor of Medicine and Chief, Division of Endocrinology and Metabolism John.

Diabetes Prevention for a Heterogeneous Population Richard Arakaki, M.D. Professor of Medicine and Chief, Division of Endocrinology and Metabolism John.
Patient-directed titration to achieve glycaemic goals in type 2 diabetes using once-daily basal insulin: results of the TITRATE randomized controlled trial.

Patient-directed titration to achieve glycaemic goals in type 2 diabetes using once-daily basal insulin: results of the TITRATE randomized controlled trial.
Date of download: 7/5/2016 From: Inhaled Insulin Improves Glycemic Control When Substituted for or Added to Oral Combination Therapy in Type 2 Diabetes:

Date of download: 7/5/2016 From: Inhaled Insulin Improves Glycemic Control When Substituted for or Added to Oral Combination Therapy in Type 2 Diabetes:
Figure 1. Mass of rapid insulin secretory bursts and ApEn values in young and old subjects. Increased Disorderliness of Basal Insulin Release, Attenuated.

Figure 1. Mass of rapid insulin secretory bursts and ApEn values in young and old subjects. Increased Disorderliness of Basal Insulin Release, Attenuated.
Figure 2. ROC curves for fasting values (A) and OGTT values (B) for detecting insulin resistance in PCOS women. Sensitivity is plotted against 1 − specificity.

Figure 2. ROC curves for fasting values (A) and OGTT values (B) for detecting insulin resistance in PCOS women. Sensitivity is plotted against 1 − specificity.
Copyright © 2003 American Medical Association. All rights reserved.

Copyright © 2003 American Medical Association. All rights reserved.
Figure 2. Summary of trial events

Figure 2. Summary of trial events
Figure 1. Twenty-four-hour plasma ACTH concentrations in insomniacs (▪) and controls (○). The thick black line indicates the sleep recording period. The.

Figure 1. Twenty-four-hour plasma ACTH concentrations in insomniacs (▪) and controls (○). The thick black line indicates the sleep recording period. The.
Volume 26, Issue 2, Pages e2 (August 2017)

Volume 26, Issue 2, Pages e2 (August 2017)
Fig. 1. Time line for investigations

Fig. 1. Time line for investigations
Fig. 1. Kaplan-Meir survival curves for Stoke Cushing's patients, with follow-up duration in years on the x-axis. Number of patients in each subgroup is.

Fig. 1. Kaplan-Meir survival curves for Stoke Cushing's patients, with follow-up duration in years on the x-axis. Number of patients in each subgroup is.
Fig. 1. Mean BMI and BMI Z-score (se) of the children with AA, TA, and TT genotypes in rs9939609 of the FTO gene. The P values are for the additive model.

Fig. 1. Mean BMI and BMI Z-score (se) of the children with AA, TA, and TT genotypes in rs of the FTO gene. The P values are for the additive model.
Fig. 1. Correlation of TSH with TC, LDL-C, HDL-C, and TG.

Fig. 1. Correlation of TSH with TC, LDL-C, HDL-C, and TG.
Figure 2 Top panel shows mean (SE) differences in near-final height (cm) (n = 71) in the AI, GH, and AI/GH groups regardless of length of treatment (n.

Figure 2 Top panel shows mean (SE) differences in near-final height (cm) (n = 71) in the AI, GH, and AI/GH groups regardless of length of treatment (n.
Fig. 1. Study enrollment and disposition of participants

Fig. 1. Study enrollment and disposition of participants
Fig. 2. Plasma melatonin secretion profiles for each of the eight subjects across the three conditions in the study. Profiles are shown for the entire.

Fig. 2. Plasma melatonin secretion profiles for each of the eight subjects across the three conditions in the study. Profiles are shown for the entire.
Copyright © 2017 American Academy of Pediatrics.

Copyright © 2017 American Academy of Pediatrics.
Copyright © 2011 American Medical Association. All rights reserved.

Copyright © 2011 American Medical Association. All rights reserved.

Similar presentations

Ads by Google